-
Choriogonadotropin alfa
- indication:For the treatment of female infertility
- pharmacologypharmacology:
- mechanism: Choriogonadotropin alfa binds to the Follicle stimulating hormone receptor which results in ovulation in the absence of sufficient endogenous Luteinizing hormone.
- toxicity:
- absorprion: The mean absolute bioavailability following a single subcutaneous injection to healthy female volunteers is about 40%.
- halflife: The mean terminal half-life is about 29 ± 6 hours (initial half-life is 4.5 ± 0.5 hours).
- roouteelimination: One-tenth of the dose is excreted in the urine.
- volumedistribution: * 5.9 ± 1.0 L
- clearance: * 0.29 +/- 0.04 L/h [healthy down-regulated females]